Monday, September 30, 2013

Will a Recent Settlement Allow JPMorgan Chase to Grow?

With shares of JPMorgan Chase (NYSE:JPM) trading around $53, is JPM an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

JPMorgan Chase is a financial holding company that provides various financial services worldwide. The company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management, and private equity. Financial services companies like JPMorgan Chase are essential for well-functioning economies around the world.

JPMorgan Chase has reached a settlement with regulators in the U.S. and the U.K. over the $6 billion London Whale trading scandal, agreeing to pay $800 million in fines and admit wrongdoing, which could lead to more private lawsuits. According to a report from the New York Times, the admission of wrongdoing is “groundbreaking,” but the paper still noted the JPMorgan's senior executives got away without charges. The bank is still facing another fine from the Commodity Futures Trading Commission.

T = Technicals on the Stock Chart Are Mixed

JPMorgan Chase stock has been moving higher in recent years. The stock is currently trading near prices not seen since before the Financial Crisis. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, JPMorgan Chase is trading between its key averages, which signal neutral price action in the near-term.

JPM

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of JPMorgan Chase options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

JPMorgan Chase Options

25.49%

56%

55%

What does this mean? This means that investors or traders are buying a significant amount of call and put options contracts as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

October Options

Flat

Average

November Options

Flat

Average

As of today, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a significant amount of call and put option contracts and are leaning neutral to bullish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on JPMorgan Chase’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for JPMorgan Chase look like and more importantly, how did the markets like these numbers?

2013 Q2

2013 Q1

2012 Q4

2012 Q3

Earnings Growth (Y-O-Y)

32.23%

33.61%

54.89%

37.25%

Revenue Growth (Y-O-Y)

13.67%

-3.57%

10.16%

5.82%

Earnings Reaction

-0.30%

-0.60%

1.01%

-1.14%

JPMorgan Chase has seen increasing earnings and revenue figures over the last four quarters. From these numbers, the markets have expected more from JPMorgan Chase’s recent earnings announcements.

P = Weak Relative Performance Versus Peers and Sector

How has JPMorgan Chase stock done relative to its peers, Bank of America (NYSE:BAC), Citigroup (NYSE:C), Wells Fargo (NYSE:WFC), and sector?

JPMorgan Chase

Bank of America

Citigroup

Wells Fargo

Sector

Year-to-Date Return

20.64%

24.50%

28.77%

24.77%

22.14%

JPMorgan Chase has been a poor relative performer, year-to-date.

Conclusion

JPMorgan Chase is a bellwether in the banking and financial space that forms an essential part of the United States financial system. The company has reached a settlement with the United States and U.K. over the London Whale trading incident. The stock has been steadily rising and is currently trading at prices not seen since before the Financial Crisis. Over the last four quarters, earnings and revenues have been rising, however, investors have expected more from the company. Relative to its peers and sector, JPMorgan Chase has been a weak year-to-date performer. Look for JPMorgan Chase to catch-up and OUTPERFORM.

Market Wrap-Up for Sept. 5 (WAG, LTD, CPB, DE, more)

Out of the gate today, stocks rose mostly higher, as investors went into buy mode following the release of a number of economic indicators that beat analysts’ estimates. However, that bit of euphoria soon wore off and stocks came back to earth, especially as the yield on the 10 Year U.S Treasury Note started to close in on 3.00%. By the close, the major indices were just able to squeak out gains.

Stocks on the Rise

Among the stocks that closed in positive territory today were Alliant Technologies (ATK), Carlyle Group (CG), and Kaydon Corp. (KDN), after these companies announced various acquisitions. Walgreen Company (WAG) shares rallied as well, following its release of better-than-expected August sales.

Furthermore, Omnicom Group (OMC) and Humana Inc. (HUM) shares rose into positive territory following Wall Street analysts’ upgrades.

Stocks on the Decline

In contrast, shares of L Brands (LTD

Sunday, September 29, 2013

Jefferies Upgrades Federal Realty Investment Trust to “Buy”; Lowers Outlook (FRT)

Jefferies reported on Wednesday that it has upgraded real estate investment trust Federal Realty Investment Trust (FRT).

The firm has raised its rating on FRT from “Hold” to “Buy,” and has increased the company’s price target from $112 to $116. This price target suggests a 13% upside from the stock’s current price of $100.75.

Analyst Omotayo Okusanya noted: “Based on our recent tour of Assembly Row, we are now convinced about the long term value of this development project. Our recent management meetings on Sept 4th also indicate that: 1) development projects at Pike and Rose as well as Santana Row remain on track and 2) FRT remains on track to keep generating industry leading SS NOI growth. With FRT also well positioned for rising rates, we find the story compelling and upgrade the stock to Buy from Hold.”

Looking ahead, the firm has cut its estimates for FY2013 from $4.64 to $4.62 per share. FY2014 estimates have also been lowered from $4.97 to $4.96 per share.

Federal Realty Investment Trust shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

Timid Tuesday – Indexes get Gun-Shy as they Re-Test the Tops

SPY 5 MINUTEThat was disappointing!

Things started out very exciting as we opened the S&P at 1,704 and ran all the way to 1,705 for a second there, just after noon but then reality stepped in and ruined the mood.  The Dollar had bottomed out at 81.13 but bounced back 0.5% to 81.55 and that, of course, took the S&P down 0.5% (because they have that kind of relationship) and we had a sad little close.  

On Dave Fry's SPY chart, it's 170 but, on the Index itself, we're testing 1,690 in the Futures this morning, down from 1,703.75 at yesterday's highs – pretty much the same thing but our goal for the index is 1,709.67 – that's the August 2nd high and that's what needs to be cracked on this run or the next time we test our +5% line at 1,680, it may not hold. 

Speaking of lines, it's no surprise, looking at our Big Chart, that the Nasdaq pulled back hard yesterday, dropping about 40 points (1%) from it's silly open to the more realistic close at 3,718.  As you can see from our spreadsheet (which is the real Big Chart, the rest is just illustration) the invisible string between the Nasdaq, the NYSE and the NYSE (both still below the Must Hold lines) was stretched more than 10% and either they had to go up or the Nasdaq had to come down.  

Of course AAPL tends to warp the Nasdaq but AAPL is DOWN $50 since the August highs and that's 10% so it SHOULD have a 1.4% drag (now 14% of the Nasdaq) on the Nasdaq but the Nasdaq is HIGHER than it was in August, when it was just below 3,700.  So, if AAPL is dragging the Nasdaq 1.4% lower but the Nasdaq is, in fact, 2% higher – then QCOM (7%), MSFT (5.5%), ORCL (4%) GOOG (4%), INTC (3%), RIMM (3%), CSCO (2.5%), AMZN (2.5%) as well as ATVI, EBAY, BIDU, COST, FSLR, NWSA, SBUX, PCLN, etc (1%ish) must be MORE than pulling their weight.  

That means the SQQQ ETF (ultra-short Nasdaq) is a nice way to protect yourself from a broad-market pullback.  SQQQ is $21.66…
continue reading


Would you like to read up-to-date articles on the day they are posted? Subscribe by clicking here.

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Dow Gains 150 Points, S&P 500 Nears Record High as Stocks Surge on Summers Exit

Is Wednesday’s Fed meeting superfluous? Based on today’s reaction to the announcement that Larry Summers had taken himself out of contention to be the next Fed chief, it just might be.

REUTERS

The Dow Jones Industrials have gained 151 points, or 1%, to 15,527.07 today, while the S&P 500 has risen 0.8% to 1,701.64. The Nasdaq Composite has advanced 0.4% to 3,738.58.

Everyone’s focus was supposed to be on the Fed meeting wednesday, where investors would learn whether tapering was actually going to begin. Instead, Larry Summers announced that he would not seek to take over for the departing Ben Bernanke and market rallied. That suggests the market might care more about who will head the Federal Reserve after BErnanke’s term ends in 2014, more than the beginning of tapering.

 Deutsche Bank’s Jim Reid explains what comes next:

Well a highly anticipated week has started with a bang as late last night Summers pulled out of the race to be the next Fed Governor after what was becoming an increasingly difficult political battle for him to win. In a week where the FOMC will likely start to taper QE…the market will at the margin see his withdrawal as one which prolongs unorthodox policy for longer – partly because it moves the more dovish Yellen up the favourites list for the new job.

So with Summers withdrawing from the Fed race, the two other top contenders mentioned by President Barack Obama for the Fed job are Janet Yellen and Donald Kohn, the Fed’s current vice and previous Fed vice chairpersons respectively. A number of media reports suggest that it's still possible that Obama could turn to other "dark horse" candidates such as former Treasury Secretary Timothy Geithner or former Fed Vice Chairman Roger Ferguson. Geithner though was quoted this morning reaffirming his disinterest in leading the Fed (WSJ).

Marketfield’s Michael Shaoul calls the Summers announcement noise:

We would also stress how unimportant all of this is over the medium to longer term. We never saw any great difference between Summers and Yellen since neither candidate seemed to recognize the degree to which FOMC policy has fallen behind the trajectory of the US economy. We also believe we have reached the point at which FOMC accommodation has started to actually undermine the foundations of the bond market, as the risks of an inflationary impulse start to grow in stronger portions of the US economy. We have also reached the point at which bond returns simply cannot keep up with equities, and even today’s rally in bonds seems likely to be a fraction of the gains for those enjoyed by the broad US equity market, which looks to be pushing further into blue sky territory.

Therefore while this morning’s violent rally may bring some much needed respite to those heavily exposed to the bond market it is likely to blow over soon enough and be replaced by another grind towards higher yields and lower prices as investment capital continues to head for the exits. Clearly the risks of an imminent breakdown in the bond market have diminished for the time-being, but we would still expect substantial difficulties to be encountered in the weeks ahead making this rally an excellent selling opportunity for those who remain over-exposed to fixed income.

And the taper? Let’s wait until Wednesday.

Blyth (BTH) has gained 10% to $14.25 this morning in what could be a short squeeze.

Packaging Corp. of America (PKG) has jumped 6.3% to $57.99 after it said it would buy Boise (BZ) for $1.28 billion. Boise has gained 26% to $12.55.

Allegheny Technologies Incorporated (ATI) has gained 9.7% to $31.41 after it said it would sell its tungsten business to Kennametal (KMT). Kennametal has risen 2% to $46.92.

Friday, September 27, 2013

Will Rising Interest Rates Doom MLPs?

The market continues to hop along on its pogo stick before and after every meeting of the Federal Reserve, and in the master limited partnership space, the effect is quite exaggerated. In this video, Fool.com contributor Aimee Duffy spells out exactly what MLP investors can expect when the Fed finally tapers, and why that might be the perfect buying opportunity for some of our favorite MLPs.

Dividend Stocks Can Make You Rich
It's as simple as that. Over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Best Clean Energy Companies To Watch For 2014

The recent budget proposal from the Obama administration is taking a lot of criticism for its big emphasis on clean energy technology development. While some may critique the method on how this will be funded, others fear the possibility of these clean energy investments failing,�the most recent and most widely publicized example being the bankrupt solar company Solyndra.�

Yet while we rake the muck of these failed�investments, many of us look over the fact that several industries and technologies were made possible from government funding.�Clearly, not every investment the government makes will be a great success, but�several�successful�businesses have developed in large part because of government assistance. There are examples across almost every sector of industry, but for now let's focus on developments in energy and see if a failure like Solyndra is an�aberration or just part of everyday business for the government.

Best Clean Energy Companies To Watch For 2014: Allot Communications Ltd.(ALLT)

Allot Communications Ltd. engages in developing, selling, and marketing Internet protocol service optimization and revenue generation solutions in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. Its solutions are used to create policies to monitor network applications, enforce quality of service policies that guarantee mission-critical application performance, mitigate security risks, and leverage network infrastructure investments. The company offers traffic management systems, including Service Gateway platform for broadband service control and optimization based on DPI; and NetEnforcer traffic management system that inspects, monitors, and controls network traffic by application and by user. Its network management application suites comprise NetXplorer that provides service providers and enterprise customers a view of traffic on the network; and Subscriber Management Platform, a system that helps service providers build an intelligent service network d esigned to deliver the quality of experience. The company also offers ServiceProtector, which ensures service continuity, and guards network integrity against known and unknown threats, as well as enables surgical mitigation through immediate identification of denial of service attacks, zero day attacks, worms, zombie, and botnets. In addition, it provides MediaSwift that caches and accelerates popular Internet video. The company markets and sells its products to carriers, mobile operators, cable operators, educational institutions, governments, and enterprises, as well as wireless, wireline, and satellite Internet service providers. It sells it products through distributors, resellers, OEMs, value added resellers, and system integrators, as well as through direct sales. The company was formerly known as Ariadne Ltd. and changed its name to Allot Communications Ltd. in September 1997. Allot Communications Ltd. was founded in 1996 and is based in Hod-Hasharon, Israel.

Advisors' Opinion:
  • [By Jon C. Ogg]

    Allot Communications Inc. (NASDAQ: ALLT) was raised to Outperform with an $18 price target at Oppenheimer.

    Baxter International Inc. (NYSE: BAX) was added to the Conviction Buy list with an $86 price target at Goldman Sachs.

Best Clean Energy Companies To Watch For 2014: Super Micro Computer Inc.(SMCI)

Super Micro Computer, Inc., together with its subsidiaries, develops and provides high performance server solutions based on modular and open-standard architecture. The company offers a range of rackmount, workstation, storage, graphic processing unit, and blade server systems, as well as subsystems and accessories used by distributors, original equipment manufacturers, and end customers to assemble server systems. It provides server options with single, dual, and quad CPU capability supporting Intel Pentium and Xeon multi-core architectures; and server systems based on AMD dual and quad Opteron. The company also offers server subsystems and accessories, including server boards, and chassis and power supplies. In addition, it sells other system accessories, such as microprocessors, memory, and disc drives. The company sells its server systems, and server subsystems and accessories through distributors, including value added resellers, system integrators, and original equip ment manufacturers, as well as through its direct sales force primarily in the United States, Europe, and Asia. Super Micro Computer, Inc. was founded in 1993 and is headquartered in San Jose, California.

Top 5 China Stocks To Buy For 2014: Globecomm Systems Inc. (GCOM)

Globecomm Systems Inc. engages in the provision of satellite-based network solutions to government, communications service providers, commercial enterprises, and media and content broadcasters in the United States, Europe, South America, Africa, the Middle East, and Asia. It offers access products for providing data, voice, and video transport services; hosted application products for back office applications services; and professional services, including advisory and consulting services. The company also provides life cycle support services comprising installation, network monitoring, help desk, maintenance, and professional engineering services that supports access and hosted products; and infrastructure solutions, such as design, engineering, and installation of ground segment systems and networks, which are used in communications and media delivery networks. In addition, it offers fixed satellite terminals under the Summit brand; transportable satellite terminals under the Explorer brand; and network management systems to manage, monitor, and control networks under the AxxSys brand name, as well as systems design and integration products. The company was founded in 1994 and is headquartered in Hauppauge, New York.

Best Clean Energy Companies To Watch For 2014: AFI DEVELOPMENT PLC ORD USD0.001 B(AFRB.L)

AFI Development Plc, and investment holding company, operates as a real estate development company in Moscow, the Russian regions, Ukraine, and the Commonwealth of Independent States. It develops and redevelops, leases, and sells commercial and residential real estate assets, including offices, shopping centers, hotels, mixed-use properties, and residential projects. The company was founded in 2001 and is based in Limassol, Cyprus. AFI Development Plc is a subsidiary of Africa Israel Investments Limited

Best Clean Energy Companies To Watch For 2014: Metro Holdings Limited (M01.SI)

Metro Holdings Limited, together with its subsidiaries, engages in the property development and investment, and retail businesses primarily in the People�s Republic of China, Indonesia, and Singapore. It operates in two segments, Retail and Property. The Retail segment operates a chain of department stores and specialty stores, which offer a range of merchandise, fashion accessories, and casual women�s wear. This segment serves customers through a chain of four Metro department stores; eight Monsoon/Accessorize/M.2 specialty store in Singapore; and eight department stores in Indonesia. The Property segment engages in leasing shopping and office spaces; and investing in property-related businesses. This segment has interests in 143,000 square meters of retail and office properties in Beijing, Shanghai, and Guangzhou. Metro Holdings Limited was founded in 1957 and is based in Singapore.

Wednesday, September 25, 2013

OK, Now It's Safe to Dive Into Sutor Technology Group (SUTR)

To tell the truth, I had almost forgotten about Sutor Technology Group Ltd. (NASDAQ:SUTR) after posting my "right stock, wrong time" speech back on the 9th. While I loved the way SUTR had broken past a horizontal ceiling at $1.83 after several weeks' worth of trying, the bullish move itself was a little overheated and looked like it was setting up a near-term pullback. Only after that dip would the stock be a healthy buy again.

As it turns out, though SUTR ended up gaining another 18% (+$0.38) after the 9th before reaching its high of $2.42 on the 16th, the stock did finally end up doling out that pullback. Good news though...that pullback was more than enough for Sutor Technology Group shares to hit the proverbial "reset" button on the rally, making it safe to wade back into a position. In fact, given the subtle clues behind the pullback's bars, it would be surprising if SUTR didn't rekindle the rally here.

For starters, Sutor Technology Group Ltd. simply brushed that former floor at $1.83 with yesterday's deep low, and immediately rebounded into what ended up being a gain for the day. When former ceilings turn into floors - as $1.83 did - they should be taken seriously... they're likely for real. That being said, even without the brush of the $1.83 level on Wednesday, the shape of the bar from yesterday still screams upside reversal. The open and the close were at or near the high for the day (a day with a very tall high/low range). That's, for the most part, a doji bar, which when they materialize after a sharp pullback generally indicate the transition from a net-bearish environment to a net-bullish one. Take a look.

All of that aside, if nothing else you can see how all of Sutor Technology Group's moving average lines are now sloped upward, confirming the trend is bullish in all the key timeframes.

Bottom line: SUTR may still be a little wobbly for a few more sessions, but the heavy lifting's been done; shares are above and beyond the big line in the sand at $1.83. And, Sutor Technology Group shares were already above a key resistance line in the weekly timeframe. There's still an element of risk to any small cap stock, but from a technical perspective, there's not a lot of risk left with this chart.

For more trading ideas and insights like this one, sign up for the free SmallCap Network daily newsletter. It's chock full of stock picks, market calls, and more. Subscribe today.

Tuesday, September 24, 2013

U.S. Consumers Borrowing More Again

The Federal Reserve reported on Monday afternoon that total outstanding U.S. consumer credit rose 4.4% in July, from a revised estimate of $2.842 trillion in June to $2.852 trillion. A total of $850 billion is revolving credit while $2 trillion is non-revolving. Consumer credit in the Fed's G.19 report includes short- and medium-term credit to individuals, and does not include home mortgages.

Revolving credit, which includes credit card debt, was down 2.6% in July after dropping 5.2% in June. Non-revolving credit, which includes car loans and student student loans, rose 7.4% in July after a 9.5% jump in June.

The jump in new car sales in July likely drove the non-revolving portion of consumer debt. Another jump could then be predicted for August, when new car sales were even higher than they were in July.

As for student loans, JPMorgan Chase & Co. (NYSE: JPM) announced last week that it planned to get out of the student lending business as more scrutiny from regulators and federal government programs are taking a larger share of the business. The federal government's consumer lending total in July was $571.9 billion, more than triple the total outstanding at the end of 2010.

Monday, September 23, 2013

10 Best Biotech Stocks To Watch For 2014

Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals (NASDAQ: QCOR  ) is taking. The biotech announced today that it has acquired rights to develop Syncathen and�Synacthen Depot in the U.S. from�Novartis (NYSE: NVS  ) . Questcor is paying $60 million up front and at least $75 million over the next few years, plus potential milestone payments. Shares were up nearly 25% in early trading.

What it means
Questcor appears to be playing both defense and offense with this move. On the defensive front, buying rights to Synacthen makes a lot of sense. Synacthen is a synthetic version of adrenocorticotropic hormone, or ACTH, which is the active ingredient in Acthar.

There's at least one big difference between Acthar and Synacthen, though. Questcor charges $28,000 per vial for Acthar. Synacthen Depot sells for around 3% of the cost of Acthar. You read that right -- Acthar costs 30 times more than the its synthetic rival.

10 Best Biotech Stocks To Watch For 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

10 Best Biotech Stocks To Watch For 2014: DiaMedica Inc (DMA)

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.

Top Penny Stocks To Buy For 2014: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

10 Best Biotech Stocks To Watch For 2014: Quintiles Transnational Holdings Inc (Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company operates in two segments: Product Development and Integrated Healthcare Services. The Company�� Product Development segment operates as a contract research organization (CRO) focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company�� Integrated Healthcare Services segment is a global commercial pharmaceutical sales and service organizations and Integrated Healthcare Services provides a range of services, including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as healthcare business services for the healthcare sector, such as outcome-based and payer and provider services. In August 2012, it acquired Expression Analysis, Inc.

Product Development

Product Development provides services and that allow biopharmaceutical companies to outsource the clinical development process from first in man trials to post-launch monitoring. The Company�� service offering provides the support and functional necessary at each stage of development, as well as the systems and analytical capabilities. Product Development consists of clinical solutions and services and consulting. Clinical solutions and services provides services necessary to develop biopharmaceutical products, including project management and clinical monitoring functions for conducting multi-site trials (generally Phase II-IV) (core clinical) and clinical trial support services that improve clinical trial decision making and include global laboratories, data management, biostatistical, safety and pharmacovigilance, and early clinical development trials, and strategic planning and design services that improve decisions and performance. Consulting provides strategy and management consulting services based on life science and advanced analytics, as well as regulatory and comp! liance consulting services.

The Company competes with Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc. (inVentive), INC Research and PRA International.

Integrated Healthcare Services

Integrated Healthcare Services provides the healthcare industry with both geographic presence and commercial capabilities. The Company�� commercialization services are designed to accelerate the commercial of biopharmaceutical and other health-related products. Service offerings include commercial services (sales representatives, strategy, marketing communications and other areas related to commercialization), outcome research (drug therapy analysis, real-world research and evidence-based medicine, including research studies to prove a drug�� value) and payer and provider services comparative and cost-effectiveness research capabilities, clinical management analytics, decision support services, medication adherence and health outcome optimization services, and Web-based systems for measuring quality improvement.

The Company competes with inVentiv, PDI, Inc., Publicis Selling Solutions, United Drug plc, EPS Corporation and CMIC HOLDINGS Co., Ltd.

10 Best Biotech Stocks To Watch For 2014: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Advisors' Opinion:
  • [By Paul Ausick]

    Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analyst�� upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.

10 Best Biotech Stocks To Watch For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

10 Best Biotech Stocks To Watch For 2014: Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

10 Best Biotech Stocks To Watch For 2014: AMAG Pharmaceuticals Inc.(AMAG)

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients. AMAG Pharmaceuticals was founded in 1981 and is based in Lexington, Massachusetts.

10 Best Biotech Stocks To Watch For 2014: OncoGenex Pharmaceuticals Inc.(OGXI)

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company?s clinical stage products include Custirsen, a phase III clinical stage product for treatment in men with metastatic castrate-resistant prostate cancer; OGX-427, which is in phase II clinical development stage is designed to inhibit heat shock protein 27; and SN2310 that completed phase I stage of clinical development is designed to evaluate safety in patients with advanced cancer. Its pre clinical stage products include GX-225 that is focused on reducing the production of IGFBP-2 and IGFBP-5; and CSP-9222, lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is based in Bothell, Washington.

10 Best Biotech Stocks To Watch For 2014: Applied Nanotech Holdings Inc (APNT)

Applied Nanotech Holdings, Inc., incorporated on May 22, 1989, is engaged in nanotechnology research and development business. The Company's nanotechnology research involves performing contract research and development services for others to develop products and materials for new applications, and then leveraging this research by applying it to other similar applications in other industries. The Company also develops intellectual property (IP) around its products and technologies. The Company develops five technology platforms: nanosensor technology; nanocomposites, based on carbon nanotube composites; thermal management materials; nanoelectronics applications, and electron emission activities, primarily in the display area. The Company's electron emission IP is divided into display activities and non-display activities. Applied Nanotech Holdings, Inc. is the parent company. Applied Nanotech, Inc. (ANI) is a subsidiary of ANHI. During the year ended December 31, 2012, the Company formed EZDiagnostix, Inc., (EZDX).

Sensors

The Company develops sensors based on ion mobility sensor technology and differential mobility spectroscopy. The Company is involved in projects to develop Mercaptan and Methane sensors for uses in the natural gas industry. The Company is also applying this technology to other applications, including agricultural pathology, wound care, and breath analysis. The Company develops hydrogen sensor for use in the measurement of hydrogen in power transformer products. The Company develops carbon monoxide sensor that can last for 10,000 hours on a single battery. The Company's carbon nanotube technology is for use in biosensors. Sensors based on carbon nanotubes or other nanomaterials can be used to detect chemical, organic, or biological warfare agents, as well as explosives, hydrogen, ammonia and numerous other chemicals.

Nanocomposites

The Company is in the advanced stages of development of nanomaterials using carbon nanotube (CNT) and! other composites. Epoxies are used in industries with worldwide markets, with applications, including adhesives, paints, coatings, and composites. In addition to epoxy resins, the Company develops other types of resins, including polyesters and vinyl esters. Vinyl esters are used in a variety of industrial applications, including storage tanks, piping, and construction. The Company develops a process for coating nylon pellets with CNTs to improves electrical conductivity. Nylon 6 with improved electrical conductivity can be used for its anti-static qualities, electrostatic discharge, and electromagnetic/RF shielding.

Thermal Management

The Company markets thermal management material called CarbAl. CarbAl provides a passive thermal management solution for temperature control issues that plague electronics manufacturers. CarbAl is a carbon based metal nanocomposite comprised of 80% carbonaceous matrix and a dispersed metal component of 20% aluminum. The Company also develops a simplified version of CarbAl based on graphite.

Conductive Inks

The Company develops aluminum and silver inks and pastes that is ideal for use in the production of solar cells. The Company also develops aluminum paste that can be used in current solar cell production.

The Company competes with Zyvex Performance Materials, GSI Creos, Amroy Europe, Ltd., DuPont and Ferro

Sunday, September 22, 2013

The Deal: AMR Secures Plan Confirmation at Last

NEW YORK (TheStreet) -- AMR Corp. (AAMRQ) has passed its final bankruptcy test and now can look ahead to a Nov. 25 antitrust trial with the Department of Justice.

Judge Sean H. Lane of the U.S. Bankruptcy Court for the Southern District of New York in Manhattan on Thursday, Sept. 12, conditionally confirmed the plan, centered on an $11 billion merger of AMR and US Airways Group (LCC).

AMR was originally set for an Aug. 15 confirmation hearing before the DOJ filed its suit against the merger on Aug. 13, causing Lane to postpone the hearing to Aug. 29 and then Sept. 12 while determining whether to confirm the plan.

"There can be no dispute that the plan is feasible if the merger is allowed to proceed," Lane said. "The real issue here is whether the pendency of the DOJ lawsuit acts as a separate bar to feasibility, and the court concludes that it does not." The DOJ was joined in its action Aug. 13 by attorneys general from six states and the District of Columbia. The government plaintiffs asserted the merger, which would form the world's largest airline, would substantially lessen competition for commercial air travel in local markets throughout the U.S. and result in passengers paying higher airfares and fees for ancillary services while receiving less service overall. Lane noted the DOJ filed a notice on Aug. 23 that said despite the suit, the agency did not object to confirmation. "The court agrees that the processes can and should proceed concurrently," Lane said. "Is there a benefit to act now? The court concludes that there is." In a Thursday statement, AMR spokesman Mike Trevino said: "The judge's ruling today shows that American is heading in the right direction. This is yet another important milestone in completing one of the most successful turnarounds in commercial aviation. We are focused on the antitrust case and will show that our planned merger with US Airways is good for consumers and competition." Lane, meanwhile, rejected a section of the plan that would have given AMR CEO Tom Horton a $19.88 million severance payment, calling it "impermissible under the Bankruptcy Code."

U.S. Trustee Tracy Hope Davis had objected to the plan based on the Horton payment.

"All the hard work Mr. Horton did was his job, as the CEO of an international airline now in bankruptcy," Davis counsel Susan Golden said at the Aug. 15 hearing. "If he didn't do his best to work hard and maximize the value of this estate, it would have been a breach of duty."

Debtor counsel Stephen Karotkin of Weil, Gotshal & Manges LLP said Horton had agreed not to fight the ruling if Lane rejected the payment. Karotkin said the debtor would revise the plan at a Sept. 18 board of directors meeting to remove the severance payment. A Thursday statement from AMR said Horton "feels that any delay or uncertainty places a further burden" on all parties involved with the plan.

Under AMR's reorganization plan, first filed April 15, secured creditors would be paid in full in cash, with the sale proceeds of their collateral or with the return of the collateral securing their claims. Secured claims include $6.78 billion in secured aircraft claims and $3.47 billion in other secured claims. Priority claims ($356.7 million) and administrative claims ($290.4 million) would be paid in full on the effective date. Priority tax claims would be paid in full within five years. Unsecured creditors would receive a pro rata share of new mandatorily convertible preferred stock. AMR owes an estimated $967.13 million in unsecured claims and $700,000 in other general unsecured claims, unit American Airlines Inc. owes $1.97 billion, and unit AMR Eagle Holding Corp. has $20.2 million in unsecured claims. Convenience claims against AMR Eagle ($2.5 million) and American Airlines ($7.5 million) would be paid in full. US Airways shareholders would get one share of common stock in the new airline at 1 cent per share for each of their shares, for a total of 28% of the diluted equity interests in the new company. The remaining 72% would be distributable to unsecured creditors, labor unions, certain employees and holders of AMR equity interests. The U.S. Airline Pilots Association would get 13.5% of new common stock, the Transport Workers Union of America AFL-CIO would get 4.8%, and the Association of Flight Attendants would get 3%. The unions are owed $1.72 billion.

All of the unions have issued statements critical of the DOJ and supporting the merger.

AMR would fund the plan with $3.25 billion in exit financing that would be secured by slots, gates and route authorities that are used to operate nonstop scheduled air carrier services between the U.S. and South America, Mexico and Central America. AMR on May 31 filed the financing motions under seal.

Lane on May 9 authorized AMR to obtain a $2.25 billion exit term loan and a $1 billion exit revolver. The term loan will be available to AMR during its bankruptcy but will convert to an exit facility on the debtor's emergence from Chapter 11. The revolver will only be available on the airline's bankruptcy exit.

Lane approved the disclosure statement for the plan on June 4. AMR was the only major U.S. airline that had not sought Chapter 11 protection until Nov. 29, 2011, when it filed its petition. AMR blamed its bankruptcy on weak financial performance since 2009, which has left the Fort Worth company behind its major rivals, many of which restructured and emerged from bankruptcy before 2009. AMR was hurt further by an uncertain economic outlook, volatile fuel prices, an uncompetitive cost structure and a diminishing financial condition, which had been the subject of industry analyst reports and the cause of speculation about a possible bankruptcy filing. Thomas A. Roberts, Glenn D. West and Alfredo P�rez of Weil Gotshal are also debtor counsel. Jones Day's Joe Sims and J. Bruce McDonald, Paul Hastings LLP's MJ Moltenbrey, Debevoise & Plimpton LLP and K&L Gates LLP are AMR's legal advisers. Rothschild's Christopher Lawrence, Homer Parkhill, Yusik Choi and Matt Chou are the airline's financial advisers. Sims is representing AMR in the DOJ lawsuit. A Barclays plc team including Josh Connor, Ben Metzger, Kristin Healy and Larry Hamdan joined with Jim Millstein of Millstein & Co. LLC to serve as financial advisers to US Airways. Latham & Watkins LLP's Peter F. Kerman, O'Melveny & Myers LLP, Cadwalader, Wickersham & Taft LLP and Dechert LLP's Paul T. Denis, Gorav Jindal and Rani Habash provide legal counsel to US Air.

O'Melveny antitrust litigator Richard Parker, a former director of the competition bureau at the Federal Trade Commission, is representing the airline in the DOJ lawsuit, along with Dechert's Denis.

A Skadden, Arps, Slate, Meagher & Flom LLP team led by John Butler and Jay Goffman, working with Togut, Segal & Segal LLP, are counsel to the official committee of unsecured creditors. Moelis & Co. LLC's William Derrough, Gregg Polle and Zul Jamal, along with Mesirow Financial Holdings Inc., are financial advisers to the committee.

Gerard Uzzi and Tom Janson of Milbank, Tweed, Hadley & McCloy LLP and Eric Siegert of Houlihan Lokey Inc. represent an ad hoc committee of AMR creditors that signed a plan support agreement.

Seabury Group LLC and Amy Caton of Kramer Levin Naftalis & Frankel LLP represent Bank of New York Mellon Corp. and Law Debenture Trust Co. of New York LLC as indenture trustees in connection with the merger negotiations. -- Written by Pat Holohan in New York

'Mad Money' Lightning Round: Wendy's Is Terrific

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the "Mad Money Lightning Round" Monday evening:

Stratasys (SSYS): "These guys just did a big secondary, so you need to wait for that to be digested before this one goes higher."

Wendy's Company (WEN): "I think that Wendy's is really terrific. If it goes down, buy some." Zoetis (ZTS): "This is a great, fast-growing company. I like this idea." Ciena (CIEN): "It's not too high. I'd buy half and buy more if it pulls back. It's an incredible story." Coty (COTY): "No, I don't see them doing well. They need to do an acquisition. It's a bummer." International Game Technology (IGT): "These casinos are flush and buying equipment. " To read a full recap of "Mad Money" on CNBC, click here. To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

The Deal: Europe, Asia Stocks Rise as Fed Doesn't Taper

LONDON (The Deal) -- The Federal Reserve's surprise retreat Wednesday from the brink of monetary tightening unleashed a wave of euphoria across stock markets in Asia and Europe Thursday.

The Fed unexpectedly decided to avoid a so-called taper on its monthly bond repurchases, maintaining the level at $85 billion, amid signs the U.S. economy still requires central bank support. [Read: 5 Stocks Under $10 Set to Soar]

European stock indices rose to five-year highs. The DAX climbed 101.30, or 1.17%, to 8,737.36, while the FTSE 100 rose 90.34, or 1.38%, to 6,649.16, with large gainers including resources companies and banks.

A Delaware court ruling will delay a plan by French media and telecom company Vivendi to sell over $8 billion of shares in its Activision Blizzard (ATVI) gaming affiliate. The court ruled a share $2.34 billion purchase from Vivendi by a group led by Activision co-Chairman Brian Kelly and CEO Bobby Kotick must be cleared by shareholders other than Vivendi. The Vivendi plan also includes selling back to Activision another $5.83 billion of stock. Vivendi shares in Paris slipped €0.05 (6.8 cents) to €17.405 as investors bet that the deal will eventually go through after a delay. [Read: JPMorgan Whale Fines for Dummies: An Explainer] In the Netherlands, ING Groep (ING) offered more information about its long-awaited, European Commission-mandated splitoff of European insurance unit from its banking activities. It said it may conduct this through a partial spinoff in 2014, rather than via a straight IP0. Its shares edged up €0.038, or 0.42%, to €9.023. In Asia, the Nikkei closed up 260.82, or 1.80%, at 14,766.18 and the Hang Seng gained 385.06, or 1.67%, to close at 23,502.51. Standard & Poor's futures edged up 0.31% at 1,723.10.

Saturday, September 21, 2013

JPM Faces 'Months' of Regulatory Pain: Dimon

NEW YORK (TheStreet) -- There's no end in sight for the continuing flow of regulatory leaks, expensive cash settlements and negative headlines for JPMorgan Chase (JPM), according to CEO James Dimon.

In an interoffice memo leaked to news outlets Tuesday, Dimon warned of "more to come" in the "weeks and months" ahead, regarding "legal and regulatory issues facing our company." He also said the company was taking extraordinary measures to deal with those challenges, measures evidenced by plans to hire thousands of new workers.

Numerous reports have indicated JPMorgan was ready to pay fines of up to $700 million or $800 million to settle with the Department of Justice and federal bank regulators over misconduct related to the "London Whale" hedge trading losses last year. The Wall Street Journal on Tuesday reported that the Commodity Futures Trading Commission was also conducting a London Whale-related investigation.

According to the unnamed sources cited in the Journal report the CFTC is "focusing on a giant trading position that enforcement officials believe distorted prices and misled investors," during 2012. Despite the reported large settlement, JPMorgan -- the company, and not individual employees, some of whom have already been indicted over the London Whale fiasco -- is still facing possible criminal charges from the Justice Department. JPMorgan is facing $4 billion in expenses and fees related to the mounting regulatory challenges it faces. Meanwhile, two ex-JPMorgan traders were indicted for their role in the $6.2 billion trading loss known as the London "Whale." The indictments were unsealed in a Manhattan court Tuesday. The charge of securities fraud carries a maximum sentence of 20 years in prison. The indictment names Javier Martin-Artajo, who oversaw trading strategy for the synthetic portfolio at the bank's chief investment office in London, and Julien Grout, a trader who worked for him, in the indictment. According to media accounts of Tuesday's hearing, a lawyer for Grout accused the prosecution of being politically motivated and declared Grout's innocence. The defense argument is seeking to portray Grout as a lower-level employee merely following the instructions of his managers. -- Written by TheStreet staff in New York

Wall Street Seems All In on Adobe

NEW YORK (TheStreet) -- Software giant Adobe (ADBE), which is due to report third-quarter earnings on Tuesday, has become (on many levels) a very interesting story. Without a doubt, this company still has a say not only in the world of digital media, but also in content distribution and consumption.

But it's unclear, though, whether management can effectively prioritize the company's collective ambitions.

You see, over the past couple of years, Adobe has struggled to grow revenue and margins on its once-dominant creative suite applications -- the one that includes popular titles like Pagemaker and Dreamweaver. Free offerings from rivals like Google (GOOG) and software alternatives from Apple (AAPL) and Microsoft (MSFT), began eating into Adobe's market share. Not to mention, each of these companies had cloud-distribution advantages, an area Adobe had yet to adopt. [Read: More Than Porn: Shame and Masculinity in the 21st Century]

In a case of "if you can't beat them, join them," Adobe has been working to transition its business from software sold in a box to a cloud/subscription-based model. On top of that, Adobe recently announced a $600 million all-cash deal to acquire Neolane, a privately held French company France that specializes in cross-channel campaigns. Given Neolane's capabilities in online and offline marketing, I won't dispute that this acquisition makes perfect sense. But again, given Adobe's transition, I have to question the timing. And I believe that this just might have been a case where management has bitten off more than it can chew. The other concern is with Adobe's digital media business, which has been -- as I said --shedding revenue, including a drop of 18% in the June quarter. I appreciate that management has decided to move away from this business. But it's still an important source of cash flow. Not to mention, this brings up a very important question: To what extent can Adobe offset these declines, while (at the same time) implementing a new business model, given Neolane's annual revenue of (only) $60 million, which amounts to just 1% of Adobe's 2012 total sales of $4.4 billion? To be perfectly honest, beyond the software synergies, I'm not seeing what Adobe hopes to accomplish here.

Bulls will argue that Neolane is posting 40% revenue growth, but so what.

I can give Neolane all of the credit it deserves, but it still pales in comparison to the offerings of Oracle (ORCL) and Salesforce.com (CRM) -- two giants with similar (and perhaps better) marketing capabilities. And the idea that this acquisition suddenly catapults Adobe as a threat to either of these companies is premature, if not entirely far-fetched. [Read: Apple's iPhones Are Built for Collect Calls]

I'm not just here beating up on Adobe. On more than one occasion, I've applauded the progress that the company has made. And given how well customers -- both current and new -- have embraced the company's new cloud platform, which now totals more than 700,000 paid subscribers, I can tell you that the transition has gone better than expected.

But that's not the whole picture. There's still the issue of profitability to deal with. Let's not forget that in the June quarter, the company posted a 2% drop in GAAP gross margin, while GAAP operating income plummeted by more than 60%. The Street, meanwhile, does not seem to care. Betting that Adobe would eventually get its house in order and overcome these challenges, investors have rewarded Adobe with a P/E of 43, which includes year-to-date gains of 30%. Look, I'm not saying that this level of confidence is unjustified. But, given the many simultaneous directions in which Adobe is heading, I just don't believe there are enough data at the moment to suggest that this stock should go any higher. At the time of publication, the author was long AAPL. Follow @saintssense

Richard Saintvilus is a co-founder of StockSaints.com where he serves as CEO and editor-in-chief. After 20 years in the IT industry, including 5 years as a high school computer teacher, Saintvilus decided his second act would be as a stock analyst - bringing logic from an investor's point of view. His goal is to remove the complicated aspect of investing and present it to readers in a way that makes sense. His background in engineering has provided him with strong analytical skills. That, along with 15 years of trading and investing, has given him the tools needed to assess equities and appraise value. Richard is a Warren Buffett disciple who bases investment decisions on the quality of a company's management, growth aspects, return on equity, and price-to-earnings ratio. His work has been featured on CNBC, Yahoo! Finance, MSN Money, Forbes, Motley Fool and numerous other outlets. Follow @saintssense

Wednesday, September 18, 2013

Hot Oil Stocks To Own Right Now

Looking toward the future, I'm sure most Argentinians have their eyes set on the 2014 World Cup. The country's national team is quite often mentioned as a serious contender to bring the Cup back to a South American country. Brazil estimates that more than 600,000 visitors will make their way there for the festivities, and some will undoubtedly filter over to Argentina. However, while the increase in tourism next June and July is likely to help the country's economy a bit, it won't come close to what Argentina's shale oil and natural gas reserves will probably contribute over a much longer time horizon.

Climbing the ranks
As the eighth largest country in the world, Argentina just might have some meaningful energy reserves located deep beneath its soil. The question of how�meaningful was answered this week, in the Energy Information Administration's release of its study of 41 countries' shale reserves. Much to its delight, I'm sure, the country well known for�La Albiceleste�ranked fourth in total recoverable shale oil reserves and second in shale natural gas.

Hot Oil Stocks To Own Right Now: Schlumberger N.V.(SLB)

Schlumberger Limited, together with its subsidiaries, supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. The company?s Oilfield Services segment provides exploration and production services; wireline technology that offers open-hole and cased-hole services; supplies engineering support, directional-drilling, measurement-while-drilling, and logging-while-drilling services; and testing services. This segment also offers well services; supplies well completion services and equipment; artificial lift; data and consulting services; geo services; and information solutions, such as consulting, software, information management system, and IT infrastructure services that support oil and gas industry. Its WesternGeco segment provides reservoir imaging, monitoring, and development services; and operates data processing centers and multiclient seismic library. This segment also offers variou s services include 3D and time-lapse (4D) seismic surveys to multi-component surveys for delineating prospects and reservoir management. The company?s M-I SWACO segment supplies drilling fluid systems to improve drilling performance; fluid systems and specialty tools to optimize wellbore productivity; production technology solutions to maximize production rates; and environmental solutions that manages waste volumes generated in drilling and production operations. Its Smith Oilfield segment designs, manufactures, and markets drill bits and borehole enlargement tools; and supplies drilling tools and services, tubular, completion services, and other related downhole solutions. The company?s Distribution segment markets pipes, valves, and fittings, as well as mill, safety, and other maintenance products. This segment also provides warehouse management, vendor integration, and inventory management services. Schlumberger Limited was founded in 1927 and is based in Houston, Texas.

Advisors' Opinion:
  • [By Rebecca Lipman]

     Together with its subsidiaries, supplies technology, integrated project management, and information solutions to the oil and gas exploration and production industries worldwide. Market cap of $91.49B. EPS growth (5-year CAGR) at 24%. According to Morgan Stanley: "Thanks to an estimated $1 billion investment per year in R&D, Schlumberger has what we consider the most advanced technology portfolio in the industry."

  • [By Brian Stoffel]

    This company has been a pick of both Jordan DiPietro and Bryan White. And both analysts have pointed to the company's opportunity for oil exploration abroad -- which is where much of the demand will soon be coming from as well.

    Bryan points out that three-fourths of the company's revenue comes from abroad, with "Brazil, the Middle East, and Africa [as] key regions where activity is expected to be robust and growing."

    Jordan adds, "[Schlumberger] has an important presence in high-growth regions of the world such as Iraq, Mexico, and Russia, and has the competitive advantage to be able to offer full services, from managing entire oil fields to drilling wells."

  • [By Victor Mora]

    Schlumberger provides essential energy products and services to consumers and companies operating around the world. The stock has not see much movement in recent years but may be getting ready to head higher. Earnings and revenue figures have mostly been increasing but investors have grown to expect more from the company. Relative to its peers and sector, Schlumberger has been an average performer. WAIT AND SEE what Schlumberger stock does this coming quarter.

Hot Oil Stocks To Own Right Now: North American Energy Partners Inc. (NOA)

North American Energy Partners Inc. provides heavy construction and mining, piling, and pipeline installation services to customers in the Canadian oil sands, industrial construction, commercial and public construction, and pipeline construction markets. The company operates in three segments: Heavy Construction and Mining, Piling, and Pipeline. The Heavy Construction and Mining segment focuses on providing surface mining support services for oil sands and other natural resources. Its activities include land clearing, stripping, muskeg removal, and overburden removal to expose the mining area; the supply of labor and equipment to supplement customers� mining fleets supporting ore mining; and provision of general support services, such as road building, repair and maintenance for mine and treatment plant operations, and hauling of sand and gravel. This segment also engages in the construction related to the expansion of existing projects-site development and infrastructure ; and the provision of environmental and tailings management services. In addition, it provides industrial site construction for mega-projects; and underground utility installation services for plant, refinery, and commercial building construction. The Piling segment installs driven, drilled, and screw piles, as well as caissons and earth retention, and stabilization systems. It also designs, manufactures, and sells screw piles and pipeline anchoring systems worldwide, as well as provides tank maintenance services to the petro-chemical industry in Canada and the United States. The Pipeline segment provides small and large diameter pipeline construction and installation services, as well as equipment rental to energy and industrial clients. The company�s fleet includes approximately 900 pieces of diversified heavy construction equipment supported by approximately 750 pieces of ancillary equipment. North American Energy Partners Inc. was founded in 1953 and is headquartered i n Calgary, Canada.

Best Stocks To Invest In: Southern Union Company(SUG)

Southern Union Company, together with its subsidiaries, engages in the gathering, processing, transportation, storage, and distribution of natural gas in the United States. It operates in three segments: Transportation and Storage, Gathering and Processing, and Distribution. The Transportation and Storage segment engages in the interstate transportation and storage of natural gas in the Midwest and from the Gulf Coast to Florida. It also provides liquefied natural gas (LNG) terminalling and regasification services. The Gathering and Processing segment involves in gathering, treating, processing, and redelivering natural gas and natural gas liquids (NGLs) in Texas and New Mexico. It operates a network of approximately 5,500 miles of natural gas and NGL pipelines, 4 cryogenic processing plants with a combined capacity of 415 MMcf/d, and 5 natural gas treating plants with a combined capacity of 585 MMcf/d. The Distribution segment engages in the local distribution of natural gas in Missouri and Massachusetts. This segment serves residential, commercial, and industrial customers through local distribution systems. The company was founded in 1932 and is based in Houston, Texas.

Advisors' Opinion:
  • [By Louis Navellier]

    Southern Union Co. (NYSE:SUG) also is involved with the gathering, processing, transportation, storage and distribution of natural gas in the U.S. Southern Union stock has jumped 74% year to date.

Hot Oil Stocks To Own Right Now: Atlas Resource Partners LP (ARP)

Atlas Resource Partners, L.P. (Atlas Resource Partners), incorporated on October 13, 2011, is an independent developer and producer of natural gas, crude oil and natural gas liquids (NGL), with operations in basins across the United States. The Company is a sponsor and manager of investment partnerships, in which it co-invests, to finance a portion of its natural gas and oil production activities. During the year ended December 31, 2012, its average daily net production was approximately 77.2 million cubic feet equivalent. On December 20, 2012, it completed the acquisition of DTE Gas Resources, LLC from DTE Energy Company. On September 24, 2012, the Company acquired Equal Energy, Ltd.�� (Equal) remaining 50% interest in approximately 8,500 net undeveloped acres included in the joint venture. On July 26, 2012, it completed the acquisition of Titan Operating, L.L.C. On April 30, 2012, it acquired certain oil and natural gas assets from Carrizo Oil & Gas, Inc. In April 2012, it acquired a 50% interest in approximately 14,500 net undeveloped acres in the oil and NGL area of the Mississippi Lime play in northwestern Oklahoma.

Through December 31, 2012, the Company owned production positions in the areas of the Barnett Shale and Marble Falls play in the Fort Worth Basin in northern Texas; the Appalachia basin, including the Marcellus Shale and the Utica Shale; the Mississippi Lime and Hunton plays in northwestern Oklahoma, and the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana and the Antrim Shale in Michigan. During 2012, the Company had ownership interests in over 525 wells in the Barnett Shale and Marble Falls play and 569.3 billion cubic feet equivalent of total proved reserves with average daily production of 31.9 million cubic feet equivalent. During 2012, the Company had ownership interests in over 10,200 wells in the Appalachian basin, including approximately 270 wells in the Marcellus Shale and 1! 12.6 billion cubic feet equivalent of total proved reserves with average daily production of 35.6 million cubic feet equivalent. During 2012, it owned 21 billion cubic feet equivalent of total proved reserves with average daily production of 1.9 million cubic feet equivalent in the Mississippi Lime and Hunton plays in northwestern Oklahoma. During 2012, the Company had average daily production of 7.8 million cubic feet equivalent in the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan.

Hot Oil Stocks To Own Right Now: Alon USA Energy Inc. (ALJ)

Alon USA Energy, Inc. engages in refining and marketing petroleum products primarily in the South Central, Southwestern, and Western regions of the United States. The company operates in three segments: Refining and Marketing, Asphalt, and Retail. The Refining and Marketing segment refines crude oil into petroleum products, including gasoline, diesel fuel, jet fuel, petrochemicals, feed stocks, asphalts, and other petroleum products. It markets finished products and blend stocks through sales and exchanges with other oil companies, state and federal governmental entities, unbranded wholesale distributors, and various other third parties. This segment also markets motor fuels to distributors under the Alon brand; and licenses Alon brand name and provides payment card processing services, advertising programs, and loyalty and other marketing programs to licensed locations. The Asphalt segment is involved in the marketing of patented tire rubber modified asphalt products; and production of paving and roofing grades of asphalt comprising performance-graded asphalts, emulsions, and cutbacks. This segment sells paving asphalt to road and materials manufacturers and highway construction/maintenance contractors; polymer modified or emulsion asphalt to highway maintenance contractors; and roofing asphalt to roofing shingle manufacturers or other industrial users. The Retail segment operates retail convenience stores that offer various grades of gasoline, diesel fuel, food products, tobacco products, non-alcoholic and alcoholic beverages, and general merchandise primarily under the 7-Eleven and Alon brands. As of December 31, 2012, it had 298 retail convenience stores located in Central and West Texas, and New Mexico. The company was founded in 2000 and is headquartered in Dallas, Texas. Alon USA Energy, Inc. is a subsidiary of Alon Israel Oil Company, Ltd.

Hot Oil Stocks To Own Right Now: Noble Corp (NE)

Noble Corporation is an offshore drilling contractor for the oil and gas industry. The Company performs contract drilling services with its fleet of 79 mobile offshore drilling units and one floating production storage and offloading unit (FPSO) located globally. As of December 31, 2011, its fleet consisted of 14 semisubmersibles, 14 drillships, 49 jackups and two submersibles. Its fleet includes 11 units under construction, which include five ultra-deepwater drillships, and six jackup rigs. As of February 15, 2012, approximately 84% of its fleet was located outside the United States in areas, which included Mexico, Brazil, the North Sea, the Mediterranean, West Africa, the Middle East, India and the Asian Pacific. During the year ended December 31, 2011, it completed construction on the Noble Bully I, a drillship, owned through a joint venture with a subsidiary of Royal Dutch Shell plc; completed construction on the Noble Bully II, a drillship, and it completed construction of Globetrotter-class drillship. As of February 15, 2012, it had 10 rigs under contract in Mexico with Pemex Exploracion y Produccion (Pemex).

During 2011, the Company conducted offshore contract drilling operations, which accounted for over 98% of its operating revenues. It conducts its contract drilling operations in the United States Gulf of Mexico, Mexico, Brazil, the North Sea, the Mediterranean, West Africa, the Middle East, India and the Asian Pacific. During 2011, revenues from Shell and its affiliates accounted for approximately 24% of its total operating revenues. During 2011, revenues from Petroleo Brasileiro S.A. (Petrobras) accounted for approximately 18% and 19% of its total operating revenues. Revenues from Pemex accounted for approximately 15%, 20% and 23% of its total operating revenues.

Semisubmersibles

Semisubmersibles are floating platforms which, by means of a water ballasting system, can be submerged to a predetermined depth so that a substantial portion of the hull is b! elow the water surface during drilling operations. As of December 31, 2011, the semisubmersible fleet consisted of 14 units, including five Noble EVA-4000 semisubmersibles; three Friede & Goldman 9500 Enhanced Pacesetter semisubmersibles; two Pentagone 85 semisubmersibles; two Bingo 9000 design unit submersibles; one Aker H-3 Twin Hull S1289 Column semisubmersible, and one Offshore Co. SCP III Mark 2 semisubmersible.

Drillships

The Company�� drillships are self-propelled vessels. These units maintain their position over the well through the use of either a fixed mooring system or a computer controlled dynamic positioning system. Its drillships are capable of drilling in water depths from 1,000 to 12,000 feet. The maximum drilling depth of its drillships ranges from 20,000 feet to 40,000 feet. As of December 31, 2011, the drillship fleet consisted of 14 units, including four drillships under construction with Hyundai Heavy Industries Co. Ltd. (HHI); three Gusto Engineering Pelican Class drillships; two Bully-class drillships to be operated by it through a 50% joint venture with a subsidiary of Shell; one dynamically positioned Globetrotter-class drillship that left the shipyard during the fourth quarter of 2011; one Globetrotter-class drillship under construction; one moored Sonat Discoverer Class drillship capable of drilling in Arctic environments; one NAM Nedlloyd-C drillship, and one moored conversion class drillship.

Jackups

As of December 31, 2011, the Company had 49 jackups in its fleet, including six jackups under construction. The rig hull includes the drilling rig, jacking system, crew quarters, loading and unloading facilities, storage areas for bulk and liquid materials, helicopter landing deck and other related equipment. All of its jackups are independent leg and cantilevered. Its jackups are capable of drilling to a maximum depth of 30,000 feet in water depths up to 400 feet.

Submersibles

The Company has two su! bmersible! s in the fleet, which are cold-stacked. Submersibles are mobile drilling platforms, which are towed to the drill site and submerged to drilling position by flooding the lower hull until it rests on the sea floor, with the upper deck above the water surface. Its submersibles are capable of drilling to a depth of 25,000 feet in water depths up to 70 feet.

Hot Oil Stocks To Own Right Now: EXCO Resources NL(XCO)

EXCO Resources, Inc., an independent oil and natural gas company, engages in the exploration, exploitation, development, and production of onshore North American oil and natural gas properties with a focus on shale resource plays. The company holds interests in various projects located in East Texas, North Louisiana, Appalachia, and the Permian Basin in west Texas. As of December 31, 2010, it had proved reserves of approximately 1.5 trillion cubic feet equivalent; and operated 7,276 wells. The company was founded in 1955 and is based in Dallas, Texas.

Advisors' Opinion:
  • [By Quickel]

    Exco Resources, Inc. (XCO) is trading around $10.70. Exco is an onshore North American oil and natural gas company, and is based in New York. These shares have traded in a range between $9.33 to $21.04 in th e last 52 weeks. XCO is estimated to earn about 78 cents per share in 2011. XCO pays a dividend of 16 cents per share which is equivalent to a 1.5% yield. The book value is stated at $7.69. In 2011, Barclays Capital set a price target of $23 per share for XCO.

Hot Oil Stocks To Own Right Now: Tesoro Petroleum Corporation(TSO)

Tesoro Corporation, together with its subsidiaries, engages in refining and marketing petroleum products in the United States. It operates in two segments, Refining and Retail. The Refining segment refines crude oil and other feed stocks into transportation fuels, such as gasoline, gasoline blendstocks, jet fuel, and diesel fuel, as well as other products, including heavy fuel oils, liquefied petroleum gas, petroleum coke, and asphalt. This segment also sells refined products in the wholesale market primarily through independent unbranded distributors; and in the bulk market primarily to independent unbranded distributors, other refining and marketing companies, utilities, railroads, airlines and marine, and industrial end-users. It owns and operates 7 refineries with a combined crude oil capacity of 665 thousand barrels per day. The Retail segment sells gasoline, diesel fuel, and convenience store items through company-operated retail stations, and third-party branded dea lers and distributors in the western United States. As of December 31, 2011, this segment had 1,175 branded retail stations under the Tesoro, Shell, and USA Gasoline brands. The company was formerly known as Tesoro Petroleum Corporation and changed its name to Tesoro Corporation in November 2004. Tesoro Corporation was founded in 1939 and is headquartered in San Antonio, Texas.